U

Ultimovacs ASA
F:7UM

Watchlist Manager
Ultimovacs ASA
F:7UM
Watchlist
Price: 1.066 EUR -0.93% Market Closed
Market Cap: 36.7m EUR

Ultimovacs ASA
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Ultimovacs ASA
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
U
Ultimovacs ASA
OSE:ULTI
Operating Income
-kr151.3m
CAGR 3-Years
3%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Operating Income
-kr111.6m
CAGR 3-Years
5%
CAGR 5-Years
-7%
CAGR 10-Years
-3%
Arcticzymes Technologies ASA
OSE:AZT
Operating Income
-kr7.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
8%
N
Nykode Therapeutics ASA
OSE:NYKD
Operating Income
-$26.5m
CAGR 3-Years
-3%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
T
Thor Medical ASA
OSE:TRMED
Operating Income
-kr33.3m
CAGR 3-Years
58%
CAGR 5-Years
41%
CAGR 10-Years
13%
Zelluna ASA
OSE:ZLNA
Operating Income
-kr217.5m
CAGR 3-Years
-11%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
No Stocks Found

Ultimovacs ASA
Glance View

Market Cap
36.7m EUR
Industry
Biotechnology

Ultimovacs AS operates as a pharmaceutical company. The company is headquartered in Oslo, Oslo. The company went IPO on 2019-06-03. The firm's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action. The firm is performing a broad clinical development program with clinical trials in Europe and the USA.

7UM Intrinsic Value
Not Available
U

See Also

What is Ultimovacs ASA's Operating Income?
Operating Income
-151.3m NOK

Based on the financial report for Dec 31, 2024, Ultimovacs ASA's Operating Income amounts to -151.3m NOK.

What is Ultimovacs ASA's Operating Income growth rate?
Operating Income CAGR 5Y
-18%

Over the last year, the Operating Income growth was 30%. The average annual Operating Income growth rates for Ultimovacs ASA have been 3% over the past three years , -18% over the past five years .

Back to Top